USSN: 09/844,544

Please make the following amendments in the Specification.

Page 1, under the title, please add the following:

## **GOVERNMENT SUPPORT**

A

This invention was made with Government support under contract Al40093 awarded by the National Institute of Allergies and Infectious Diseases. The Government has certain rights in this invention.

## Paragraphs 13-17, please replace with the following paragraphs:

- Figures 1A-L show shows a flow cytometric analysis of CD1 expression on splenic B cells. Spleen cells from 6-month-old C57BL/6 mice (A-C), 6-month-old NZB/NZW mice with proteinuria (D-F), 3-month-old C57BL/6 mice (G-I) and 3-month-old NZB/NZW mice (J-L) were stained with anti-B220-FITC or anti-IgM-FITC versus anti-CD1-Biotin (3C11 or 1B1) and counter-stained with streptavidin-PE. A subset of B220<sup>+</sup>CD1<sup>hi</sup> or IgM<sup>+</sup>CD1<sup>hi</sup> B cells is enclosed in the right box or upper-right box in each panel, and the percentage of CD1<sup>hi</sup> B cells among live nucleated cells is shown for each box. The IgM<sup>-</sup>CD1<sup>hi</sup> B cells are enclosed in the lower-right box in each panel. Each panel is representative of at least four replicate experiments.
- Figures 2 A, B and C illustrate illustrates spontaneous secretion of IgM antibodies by CD1<sup>hi</sup> B cells. Panel A shows gates for spleen cells from 6-month-old NZB/NZW mice without proteinuria after staining with anti-B220-FITC versus anti-CD1 (1B1)-PE and sorting into B220<sup>+</sup>CD1<sup>lo</sup>, B220<sup>+</sup>CD1<sup>int</sup> and B220<sup>+</sup>CD1<sup>hi</sup> subsets. The percentage of cells amongst live nucleated cells is shown for each gate. Panels B and C show concentration of IgM and IgM anti-dsDNA antibodies, respectively, in culture supernatants of each subset (5x10<sup>5</sup> cells/well) with or without syngeneic T cells (1.25x10<sup>5</sup> cells/well). Data shows the Mean ± SE of six cultures from two experiments.
- Figures 3 A and B show shows the spontaneous secretion of IgM and IgG by IgM<sup>+</sup> and B220<sup>+</sup> B cells. Panels A and B show respectively the IgM and IgG production by sorted splenic B220<sup>+</sup> and IgM<sup>+</sup> B cells (5x10<sup>5</sup> cells/well) from 6-month old NZB/NZW mice with proteinuria (> 3+). Data shows the Mean ± SE of six cultures from two experiments.
- [16] Figures 4 A, B and C illustrate illustrates the proliferation of T cells in response to stimulation by CD1 transfected A20 cells. Panels A and B show the expression of CD1 on A20 cells, a B cell lymphoma line, and CD1 transfected A20 cells (A20/CD1) by staining the

USSN: 09/844,544

cells with anti-B220 versus anti-CD1 mAbs. Panel C shows the proliferation of sorted splenic T (Thy1.2<sup>+</sup>) cells (1x10<sup>5</sup>/well) from 3-month old NZB/NZW mice co-cultured with the irradiated (5000 rads ), graded numbers of A20 or A20/CD1 cells as measured with <sup>3</sup>H-TdR incorporation. Each panel is representative of three replicate experiments.

Figures 5 A, B and C depict depicts the amelioration of lupus by *in vivo* anti-CD1 mAb treatment. Groups of 8-week old NZB/NZW mice were given 5 i.p. injections of anti-CD1 mAb or control rat lgG at a dose of 250 μg/mouse over a period of 30 days (days 0, 3, 5, 15 and 30). Thereafter, the mice were monitored with serum levels of lgG and anti-dsDNA lgG, and proteinuria and survival as shown in Panels A, B, C and D, respectively. There were 10 mice in each group. Arrows show time points of injections.